Savient Pharma (SVNT) Bouncing Around On Conference Call Comments
Tweet
Share
E-mailGet Alerts SVNT Hot Sheet
Join SI Premium – FREE
After trading lower on initial comment that it won't discuss the sales process, shares of Savient Pharmaceuticals (Nasdaq: SVNT) have bounced back on comments suggesting that it has enough funds to launch KRYSTEXXA and that the patient population is larger than what is being modeled.
After dropping 44 percent yesterday, on news that it would not be sold, trading in the name is still very volatile.
It should be noted that shares were trading at $14.76 when the company announced KRYSTEXXA approval on 9/14, which set the M&A speculation into overdrive --- currently at $12.20.
After dropping 44 percent yesterday, on news that it would not be sold, trading in the name is still very volatile.
It should be noted that shares were trading at $14.76 when the company announced KRYSTEXXA approval on 9/14, which set the M&A speculation into overdrive --- currently at $12.20.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Reddit (RDDT) added to S&P 500
- Susquehanna Downgrades The Trade Desk (TTD) to Neutral
- Planet Green halted again, now up 793%
Create E-mail Alert Related Categories
Insiders' Blog, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
